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Approximately one third of patients with epilepsy is resistant to pharmacotherapy, 
therefore studies on pathophysiology and pharmacology of epileptic seizures and epileptic 
syndromes are necessary (Engel J. Jr. and  Schwartzkroin A. P. 2006; Engel J. Jr. and Pedley 
T. A. 2008). Specific need for developmental studies is based on the fact that the number of 
newly diagnosed cases of epilepsy differs with age with the highest incidence during infancy 
and childhood. More than 75% of patients experience their first seizure before 18th year of 
life;, the first postnatal year is especially critical. Based on the epidemiology studies, seizures 
are the most frequently diagnosed symptoms in pediatric neurology  (Hauser W. A. and 
Kurland,L. T. 1975; Mathern G. W.2006).  
 
1. Neurotransmiters and the receptors 
Epilepsies are characterized by repeated appearance of epileptic seizures. Epileptic 
seizures are due to hypersynchronous activity of cerebral neurons and the pathogenetic basis 
of nearly all types of epileptic seizures is a marked predominance of excitation over 
inhibition. It is possible to elicit experimental epileptic seizures either by suppression of 
inhibition or by augmentation of excitation. Therefore main neurotransmitter systems – 
inhibitory using GABA and excitatory using glutamate as a transmitter – represent a common 
target in experimental epileptology. 
Neurotransmitters are molecules of varied nature (quaternary amines, amino acids, 
catecholamines or peptides), which are released by neurons at chemical synapses and transmit 
a message from a neuron to another neuron, or to effector cell, or a message from a sensory 
cell to a neuron (Hammond C.2001a). Since the year 1961, when Curtis and collaborators 
observed that glutamate has a depolarizing effect on neurons it is widely accepted as 
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excitatory amino acid transmitter (Hammond C.2001c). Six years later Krnjevic and Schwartz 
described that γ-aminobutyric acid (GABA) mediates inhibitory synaptic transmission in adult 
vertebrate central nervous system (CNS) (Hammond C.2001b). 
 
1.1. GABA as an inhibitory transmitter 
Majority of inhibitory synaptic transmission in the brain and spinal cord is generated 
by the small amino acid GABA. It acts on ionotropic GABAA (Fig.1) and GABAC receptors 
and metabotropic GABAB receptors. Activating the GABAA and GABAC receptor gates a Cl
- 
channel and increase Cl- influx via the postsynaptic membrane that mediates fast synaptic 
inhibition. Both types of receptors are biochemically, pharmacologically a physiologically 
different (Chebib M. and Johnston G. A. 1999). Binding of GABA on the GABAB receptor 
triggers a second messenger cascades which often activates K+ channel (Meldrum B. S.1989).  
Role of GABAB receptor in epileptic seizures is a matter of controversy. Activation of 
these receptors results in mixed anti- and proconvulsant action (e.g. Mares P. and Kubova H. 
2008). This type of GABA receptors was not studied in our experiments.  
GABAA receptor, as well as GABAC receptor, belongs to the family of 
heteropentameric ligand-gated ion channels (Ortells M. O. and Lunt G. G. 1995). This 
receptor is composed by extracellular N-terminal domain, four transmembrane components 
(TM1-TM4) and extracellular C-terminus. Large hydrophilic N-terminal domain is connected 
to TM1 and carries the neurotransmitter site and glycosylation sites. The hydrophilic loop 
separating TM3 and TM4 facing the cytoplasm contains phophorylation sites (Luscher B. and 
Keller C. A. 2004). 
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Fig. 1  GABAA receptor and its binding sites 
  
Unique structural heterogeneity of GABAA receptor has been demonstrated and 19 
different genes that encoded the subunits have been described. There are six α (α1-α6), three β 
(β1-β3), three γ (γ1-γ3), one δ, one ε, one θ, one π and three ρ (ρ1-ρ3) in mammalian CNS 
(Sieghart W. et al. 1999; Whiting P. J. et al. 1997).  The subunits stoichiometry of native 
GABAA receptors is unknown. Hypothetically, co-expression of 2α, 2 β and single γ2 subunits 
composed pentameric channel receptor and modulate the properties, which are similar to 
those of native receptor (Sieghart W. et al. 1999).  
Theoretically, the subunit diversity allows numerous combinations and the subunit co-
assembling can form homomeric or heteromeric GABAA receptors (Costa E. et al. 2002). 
However, homomeric GABAA receptor has not been identified in the brain so far. 
Furthermore, each of the δ, ε, θ and π subunits appeared to replace the γ subunit.  
The ρ-subunits form the GABAC receptor (Chebib M. 2004). Main ligand-binding site 
of the GABAC receptor is located between two neighboring subunits in extracellular part. 
GABAC receptor is very distinct from the other two GABA receptors in terms of 
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pharmacological agonist and antagonist profiles (Chebib M. and Johnston G. A. 1999; Chebib 
M. and Johnston G. A. 1999; Chebib M. 2004; Enz R. and Cutting G. R. 1998; Osolodkin D. I. 
et al. 2007). To compare with GABAA receptors, the activation with GABA is characterized 
by longer mean-open times and smaller Cl- conductance of GABAC receptors  (Feigenspan A. 
et al. 1993a; Feigenspan A. et al. 1993b). Therefore, conformationally restricted analogues of 
GABA, such as selective agonists - (+)-cis-2-aminomethylcyclopropane carboxylic acid ((+)-
CAMP) and cis-4-aminocrotonic acid (CACA)  (Chebib M. Johnston G.A. 1997; Chebib M. 
Johnston G.A. 1999); or selective antagonist - (1,2,5,6-tetrahydropyridine-4-yl) 
methylphosphinic acid (TAMPA)  (Ragozzino D. et al. 1996); have been studied to determine 
GABAC receptor profile  (Chebib M. and Johnston G.A. 1999; Chebib M. 2004; Enz R.and 
Cutting G.R. 1998; Osolodkin D. I. et al. 2007).  
The expression of the known subunits can modify different GABA sensitivity and the 
functional GABAA receptor channel properties. Moreover, the subunits localized at different 
parts of cellular surface (extrasynaptic, perisynaptic or postsynaptic sites) exhibit different 
subunit composition and properties. Extrasynapticaly and perisynapticaly localized GABAA 
receptors show high GABA sensitivity and slow inactivation. Those receptors, which exhibit 
lower GABA sensitivity and fast inactivation, are found postsynaptically (Luscher B. and 
Keller C.A.  2004).  
Majority of GABAA receptor is localized on somatodentritic compartments and axon 
initial segments of neuron. However, in the hippocampus, those receptors with α2 subunits 
have been identified at mossy fiber terminals, which contain also other potential 
neurotransmitters (Walker M. C. et al. 2002). Hypothetically, GABAA receptors with α1,2,3 
subunits mainly show synaptic localization in the cortex and hippocampus, while those 
containing α5 subunits are frequently extrasynaptic and can be seen in the olfactory bulb and 
hippocampal pyramidal cells (Costa E. et al. 2002). In the hippocampus, they probably 
contribute to the synaptic plasticity by the short-lasting repetitive synchronous firing 
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(Galarreta M. and Hestrin S. 1999). The β and γ subunits are common part of GABAA 
receptors in whole brain. 
The subunit combinations also follow expression pattern of regional distribution. The 
δ subunit shows high expression in cerebellar granule cells, thalamus and olfactory bulb 
(Galarreta M. and Hestrin S. 1999; Laurie D. J. et al. 1992). The ε subunit has very limited 
distribution and it has been found in hypothalamus and hillus of hippocampal dentate gyrus 
(Galarreta M. and Hestrin S. 1999; Whiting P. J. 1999). The π subunit, called “peripheral” 
one according to its expression in the peripheral organs such as uterus, while in the brain it 
shows very low intensity in the cortex and hippocampus (Hedblom E. and Kirkness E. F. 
1997). The regional expression of the θ subunit is similar to β one, it is seen in substantia 
nigra and striatum. Furthermore, it is abundant in tissue with catecholamines (Walker M. C. et 
al. 2002). 
The variety of subunits, which compose the GABAA receptor, can influence the 
binding affinity of different drugs and thus they can modify function of GABAA receptors. 
The endogenous (neurosteroids, GABA) as well as exogenous substances (benzodiazepines, 
barbiturates or general anesthetics) positively modulate the activity of the GABAA receptor-
Cl- channel complex. Their binding sites are localized in distinct part at the supramolecular 
complex and moreover, their action through the binding sites use different mechanisms and 
they can cause allosteric modification at other sites (Mehta A. K. and Ticku M. K. 1999; 
Sieghart W. 1995).  
Two molecules of GABA are required for confirmation change of the GABAA 
receptor channel complex and opening of chloride channel. These two sites are localized 
between α and β subunits (Hammond C.2001b).  
Clinically frequently used drugs, benzodiazepines, act trough the binding site that is 
located at the interface between α1,2,3,5 and γ subunits. They increase the opening frequency of 
Cl- channel without changing the mean burst duration or the mean number of opening per 
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burst of GABAA receptor (Costa E. et al. 2002; Hammond C.2001b). According to 
pharmacological properties of benzodiazepines heteromeric GABAA receptors containing α1 
subunits produce the sedative, amnestic and anticonvulsant activity of diazepam (Rudolph U. 
et al. 1999) and those with α2 subunits mediate anxiolytic effect (Low K. et al. 2000). 
Moreover, in the motor neurons and in the dorsal horn of spinal cord the α5, α2 or α3 subunits 
composing the GABAA receptors may produce the relaxant activity (Bohlhalter S. et al. 
1996). 
Hypnotic and antiepileptic agents, barbiturates, affect the GABAA receptor via the 
distinct binding site with the mechanism, which increase the duration of single opening and 
burst, however the frequency of channel opening is not changed (Hammond C.2001b).  
Neurosteroids are formed de novo by neuronal tissue (Baulieu E. E.1981) or can be 
produced in the brain tissue from peripheral steroid hormones such as progesterone, 
deoxycorticosterone and testosterone, which can cross blood-brain barrier (Majewska M. D. 
1992). Endogenous or synthetic neurosteroids such as epalons alter neuronal excitability by 
rapidly acting on the neuronal membrane (Gee K. W. et al. 1995). Epalons interact as positive 
allosteric modulators at a unique receptor site of the GABAA receptor-Cl
- channel complex in 
CNS (Gee K. W. 1988; Gee K. W. et al. 1995; Harrison N. L. and Simmonds M.A. 1984; 
Majewska M. D. et al. 1986). The neurosteroid mechanism is in increasing the channel open 
probability and together with GABA increase the duration of single and burst opening (Mehta 
A. K. and Ticku M. K. 1999). Epalons provide anticonvulsant activity, which is separated from 
their hormonal effects (Belelli D. et al. 1989; Gee K. W. et al. 1995).  
Reduction of the GABAA current can be mediated by the competitive antagonist, 
bicuculline by binding to the same receptor site as GABA and by channel blocker picrotoxin, 
which bind to the site localized in the ion channel. Inverse benzodiazepine agonists (such as 
β-carborbolines) reversibly decreased total GABAA current due to binding to benzodiazepine 
receptor (Hammond C.2001b). 
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 Majority of inhibitory action in adult CNS is induced by activation of resting GABAA 
receptors, where the Cl- influx induces membrane hyperpolarisation. In contrast, in immature 
hippocampus the GABAA receptor activation leads to depolarization due to high intracellular 
Cl- ions concentration and causes excitation. This changing leads to depolarization and may 
activate voltage-gated Ca2+ and NMDA-regulated channels in immature neurons (Ganguly K. 
et al. 2001).  
 
1.2. Glutamate as main excitatory transmitter 
Glutamate mediates most of the excitatory neurotransmission in the mammalian CNS. 
However, together with related excitatory amino acids it may be toxic to CNS (Collingridge 
G. L. and Leseter R. A.1989; Ozawa S. et al. 1998). Glutamate receptors are expressed mainly 
in the CNS and participate in physiological process such as synaptic plasticity, learning and 
memory, but also participate in the formation of neural networks during development (Ozawa 
S. et al. 1998). The glutamate neurotoxicity may be also involved in the genesis of various 
neurological disorders that include epilepsy, ischemic brain damage, head trauma, neuropathic 
pain and neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease, Huntington’s 
chorea and amyotrophic lateral sclerosis) (Dingledine R. et al. 1999).  
Glutamate physiological action is exerted through the activation of two types of 
receptors: ionotropic (iGluR) and metabotropic (mGluR). mGluRs are coupled to G proteins 
and control the activity of membrane enzymes and ion channels (Bockaert J. et al. 1993; 
Loscher W. 1998b). Action of glutamate on iGluRs is always excitatory but activation of 
mGluRs can result in both excitation or inhibition  (Kandel E. R. et al.2000). Traditionally, 
from the pharmacological point of view, iGluRs can be distinguished into three groups on the 
basis of their affinities and functional responses to the exogenous excitatory amino acids 
agonists N-methyl-D-aspartate (NMDA) (Fig. 2), α-amino-3-hydroxy-5-metyl-4-isoxazole 
(AMPA) and kainic acid (KA) (Meldrum B. S. 1991). In addition, another differentiation of 
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iGluRs can be made, namely to NMDA and non-NMDA receptors. The drug APV (2-amino-
5-phosphonovaleric acid), which is the antagonist on the NMDA receptors selectively blocked 
NMDA but can not modify the AMPA or KA receptors, while both of them are blocked by 
quinoxallinediones (Collingridge G. L. and Lesseter R. A. 1989; Hollmann M. and 
Heinemann S. 1994; Kandel E. R. et al.2000).  
The transmembrane topology of iGluR is different from the other ligand-gated ion 
channels such as nicotinic acetylcholine (Ach) and GABAA receptors. According to the 
Hollmann’s transmembrane topology model, these receptor subunits have in common a large 
extracellular N-terminus domain, four hydrophobic membrane segments (M1-4), three of 
them are transmembrane (M1, M2, M4) and one cytoplasm-facing re-entrant membrane loop 
(M2). The entire region between M3 and M4 is extracellular and the C-terminus is placed 
intracellularly (Dingledine R. et al. 1999).  
The function of postsynaptic iGluRs is to mediate fast excitatory synaptic transmission 
by converting the binding of glutamate to a rapid and transient increase in conduction of both 
Na+ and K+, with nearly equal permeability. Some AMPA receptors and all NMDA receptors 
are also permeable to Ca2+  (Kandel E. R. et al.2000).  
AMPA receptors are homo- and hetero-tetramers consisting of subunits known as 
GluR1-GluR4, which can mediate fast excitatory synaptic signals in the brain. By recent 
evidence, these receptors are involved in synaptic plasticity (learning and memory) 
(Dingledine R. et al. 1999; Ozawa S. et al. 1998). Similarly, KA receptors are homo- and 
hetero-tetramers and they are also responsible for excitatory synaptic transmission. 
Furthermore, they are involved in modulation of neurotransmitter release from the presynaptic 
terminal. KA receptors are composed of the subunits GluR5-GluR7, KA1 and KA2. A third 
family of iGluRs are the NMDA receptors, which are formed as heterotetramers that contain 
both of NR1 and NR2 (NR2A-NRD) subunits, in some cases NR3 (NR3A, NR3B) subunits. 
The unique properties of NMDA receptor channels are implicated in physiological functions 
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such as learning, memory as well as formation of neural networks during development 
(Dingledine R. et al. 1999; Madden D. R. 2002). 
All iGluRs are the cationic channels permeable to Na+ and K+. Some non-NMDA 
receptors and all NMDA receptors are also permeable to Ca2+. NMDA and KA receptors have 
higher affinity for glutamate than AMPA receptors (Hammond C.2001c). 
During the normal excitatory postsynaptic potential (EPSP), non-NMDA receptors are 
those, which generate the early large phase of the EPSP with permeability to Na+ and K+, but 
not to the Ca2+ ions. The AMPA receptors mediate a fast-rising EPSP, while the KA-receptor-
mediated EPSP is smaller and slower one, thus giving a slow-rising low-amplitude EPSP 
component [36]. Probably these variations in combination of the iGluRs and their subunits 
play important role in the synaptic plasticity during development (Takai H. et al. 2003). 
 
 
Fig. 2 N-methyl-D-aspartate receptor and its binding sites 
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The NMDA receptor complex is unique in comparison with the other ligand-gated ion 
channels, because for the efficient function, not only agonist but also cofactor binding and 
membrane depolarization are necessary. Thus, this receptor has a more complex role based on 
three characteristic properties. As mentioned above, NMDA receptor opens in response to 
glutamate more slowly than AMPA receptors. Requirement for glycine as another substance 
to be present together with the NMDA agonist in the extracellular space to allow opening of 
the channel complex introduces the glycine as a cofactor for proper functioning of NMDA 
receptor (Hammond C.2001c; Kandel E. R. et al.2000). Furthermore, channel opening is also 
regulated by voltage-dependent Mg2+ block. At the resting membrane potential extracellular 
Mg2+ ion binds deeply into the open NMDA channel pore and blocks the activation of the 
receptor complex. Thus ions cannot enter the intracellular space and the NMDA receptor 
component of synaptic currents is blocked. This block can be removed when the membrane is 
sufficiently depolarized and allows the influx of ions (Na+ and Ca2+) via the activated NMDA 
receptor. Therefore, glutamate first activates non-NMDA receptors (Loscher W. 1998b). The 
resting membrane can be depolarized by single activation of the co-localized postsynaptic 
non-NMDA receptors (for example, glutamate binding to the AMPA receptors). The EPSP 
response is smaller comparing to the depolarization by repeated firing of the presynaptic 
neuron that summate the EPSP (long-duration EPSP) or generate much larger current carried 
by Ca2+  (Dingledine R. et al. 1999; Kandel E. R. et al.2000). This Ca2+ influx can trigger the 
variety of intracellular signaling cascades, which can lead to changes of the certain neuronal 
functions such as long-lasting modification in the synapse and also have a close relationship 
to synaptic plasticity during CNS development (Dingledine R. et al. 1999; Kandel E. R. et 
al.2000). In contrast, the excessive Ca2+ influx through the NMDA receptors can finally, via 
the calcium-dependent proteases and phospholipases, produce free radicals, which are toxic to 
the cells and induce neuronal death (Kandel E. R. et al.2000; Takai H. et al. 2003).  
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Different studies examining subunits mRNA or protein distribution or using the 
animals with specific subunit genes deleted and comparing the functional properties of native 
and recombinant receptors have allowed to analyze different receptor channels properties. The 
GluR channel properties and their different sensitivities to the exogenous or endogenous 
substances, permeation and block by divalent ions, kinetic properties and interaction with 
intracellular proteins can be modified by subunit recombination (Cull-Candy S. et al. 2001; 
Yamakura T. and Shimoji K. 1999). 
The distribution of different subunits of NMDA and non-NMDA receptors changed 
during the development of CNS (Kandel E. R. et al.2000; Takai H. et al. 2003). In adult 
synapses both the NMDA and AMPA receptors can be present in the same postsynaptic 
membrane, while other synapses contain NMDA receptors channel complex only. In contrast 
to adult receptor combination, only NMDA receptors are displayed in the immature CNS 
(Kandel E. R. et al.2000).  
The functional characteristics of NMDA receptor channels depend on the expression 
and combination of the NR subunits during the brain maturation, which can probably explain 
the physiological and pathophysiological differences between the adult and immature CNS. 
By in situ hybridization studies at different stages of development, we can see the different 
regional distribution of the NMDA subunits in rodents (Yamakura T. and Shimoji K. 1999). It 
has been showed that NR1 subtypes strongly influence NMDA properties. In the adults, the 
NR1s are spread ubiquitously throughout the brain. Furthermore, they are localized in the 
postsynaptic densities, mainly around vesicles and associated dendrites. In contrast, the NR2s 
display distinct regional pattern. The NR2A subunits are spread all over the brain, 
predominantly in the cerebral cortex, hippocampus and cerebellum. The NR2B subunits are 
expressed in the forebrain regions such as cerebral cortex, hippocampus, septum, caudate-
putamen and olfactory bulb. The mRNA of NR2C displayed strong expression in cerebellum 
(the granule cell layer) and weak expression in the olfactory bulb and thalamus. NR2D 
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subunits are only moderately expressed in the thalamus, brain stem and the olfactory bulb. 
Both of NR2C or NR2D are probably mostly expressed at interneurons (Ozawa S. et al. 
1998).  
Recent studies showed that regional distribution of functional NMDA subunits differ 
during the brain development. During the embryonic time of CNS maturation, NR1 subunits 
are spread from the temporal region of the cerebral cortex at earlier stages to the later 
expression in the hippocampus. After birth, NR1s are distributed all over the neonatal brain 
mainly in the cerebral cortex and pyramidal cells in the hippocampus (Ozawa S. et al. 1998; 
Takai H. et al. 2003). 
The NMDA-NR2 subunits displayed different pre- and postnatal expression pattern. 
At embryonic time, NR2Bs are abundantly expressed in cerebellum (the granule cells) and 
later they are replaced by the NR2C subunits around the birth. The NR2D are detected in 
diencephalon and brain stem in the fetal brain. The NR2As are widely spread, while the 
NR2C subunits are expressed mostly in cerebellum in the neonate brain (Ozawa S. et al. 1998; 
Takai H. et al. 2003).  
The number of substances regulates the NMDA-receptor-channel efficiency in 
different ways, while at least two conditions are required for NMDA receptor activity such as 
the presence of ligand and the depolarization of the membrane (MacDermott A. B. et al. 1986; 
Meldrum B. S. 1991).  
Both, NMDA as a selective agonist and glutamate as non-selective agonist, act 
through the glutamate (glu) site of the NMDA receptor. The binding of glycine (cofactor) to a 
strychnine-intensive glycine (gly) site on the receptor increases the frequency of agonist-
induced channel opening and it is absolutely required for NMDA channel activation 
(Meldrum B. S. 1991). The extracellular Mg2+ ions regulate the NMDA receptor channel via 
Mg2+ binding site located within the channel pore by blocking the current flow. This voltage-
depended block is present at normal level of Mg2+ in the extracellular space at resting 
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membrane (Kandel E. R. et al.2000; Mayer M. L. et al. 1984; Meldrum B. S. 1991). In 
addition, there are more regulatory sites on the NMDA receptor channel, which control 
NMDA-mediated activity further (Loscher W. 1998b). The “phencyclidine (PCP) site” is 
present within the pore channel that is distinct from Mg2+ binding site. The “uncompetitive” 
NMDA receptor antagonists (NMDA receptor open-channel blockers) such as PCP, ketamine 
and MK 801 (dizocilpine) inhibit the channel opening of NMDA receptor by acting via this 
binding site (Kandel E. R. et al.2000; Meldrum B. S. 1991; Woodruff G. N. et al. 1987).  
The polyamine-binding site, when activated, modulates the NMDA current by 
increasing channel opening probability (which is due in part to an increase in glycine 
binding). Ifenprodil or eliprodil are the drugs which act as antagonist at the polyamine site 
and thereby only modulate NMDA receptor function (Lipton S. A. 1993).  
Another abundant metal (Zn2+) in CNS potently inhibits NMDA receptor activation at 
the physiological extracellular concentration. It was challenged that Zn2+ act as non-
competitive antagonist by binding to a site, which is distinct from the Mg2+ binding site and 
lies outside of the NMDA channel pore (Huang E. P. 1997; Kandel E. R. et al.2000).  
In addition, recent studies described many substances, which probably differently 
modulate the NMDA receptor, such as redox agents, nitric oxide (NO), proton (pH) and other 
compounds (Lipton S. A. 1993). 
From the pathophysiological point of view the NMDA and AMPA receptors 
contribute to seizure elaboration (Dingledine R. et al. 1990), so pharmacological strategies 
inhibiting both iGluR types might be promising (Loscher W. 1998a). 
Most AMPA receptor channels display permeability of Na+ and K+, but they do not 
conduct Ca2+. However, it was identified that there are also the Ca2+-permeable AMPA 
receptors in the CNS. The similarity of the NMDA and AMPA receptors by their permeability 
to Ca2+ ions through the channel complex is the function of the single-amino-acid (arginine 
(R) or glutamine (Q)) expressed at certain position in pore-forming M2 region of GluR2 
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subunit. When the glutamine is placed in Q/R site of the GluR2 and only Q-GluR2-subunits 
formed the AMPA receptor channel, the permeability to Ca2+ is present. While arginine 
replaced the glutamine-Q/R position just in one of the GluR2 subunits, the AMPA receptor 
channel is not permeable for Ca2+  (Dingledine R. et al. 1999; Kandel E. R. et al.2000; Ozawa 
S. et al. 1998; Seeburg P. H. 1993).  
Similarly, the subtype combinations determine the pharmacological diversity of 
NMDA receptors by changing binding affinity for the exogenous and endogenous substances 
and the influence on transmission of the receptor channel. The sensitivity of the NMDA 
receptors to glutamate is strongly supported by identification of the NR2s, while the binding 
site of cofactor glycine is placed at the NR1 subunits (Ozawa S. et al. 1998). There are 
differences in further kinetics such as deactivation time and excitatory postsynaptic current 
(EPSC) decay what is also the function of incorporation of the NR2s to NMDA receptors 
skeleton; NR2A shortens the time scale properties opposing to the NR2Ds (Cull-Candy S. et 
al. 2001; Takai H. et al. 2003). The gating characteristics of the receptor channel generating 
the “high-conductance” channel opening with high affinity to extracellular Mg2+ depend on 
NR2A or NR2B subunits. In contrast, receptors with NR2C and NR2D subunits give rise to 
low conductance with a low affinity to extracellular Mg2+ ions. Moreover this characteristic is 
also supported by evidence of “clear” NMDA receptor composition by the NR2C or NR2Ds 
in absence of NR3 subunits, which also give rise to low-conductance channel opening (Takai 
H. et al. 2003). The functional channel characteristics such as single channel properties are 
due to expression of the NR2s during development. The immature neurons mainly express the 
NR2Bs and NR2Ds, usually together with either NR2A or NR2C subunits. Furthermore, the 
NR2s expression developmental pattern depends on neuronal activity (Ozawa S. et al. 1998; 
Takai H. et al. 2003). The co-expression of NR1 and NR2 is essential for forming functional 
receptors (Grimwood S. et al. 1995).  
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2. Seizure models elicited by interaction with the main neurotransmitter 
systems 
Three developmental models were used in these studies. Pentylenetetrazol was chosen 
as a drug antagonizing GABA-A receptors, N-methyl-D-aspartate as an agonist of the most 
important type of ionotropic glutamate receptors, and flurothyl as a drug without exactly 
known mechanism of action but with a high probability without marked action on the two 
main neurotransmitter systems. 
 
2.1. PTZ-induced seizures as a developmental model 
Excitatory effect of PTZ in the brain stem has been used in the past to stimulate 
circulatory and respiratory systems in patients (Loscher W. 2009). What is still in use are 
specific epileptic phenomena elicited by PTZ in preclinical testing of potential new 
antiepileptic drugs. 
PTZ predominantly acts as an antagonist at ionotropic GABA-A receptor by binding 
to the picrotoxine site in the chloride channel (Ramanjaneyulu R .and Ticku M. K. 1984). 
PTZ is well dissolved in normal saline and in water and can be administered systematically 
subcutaneously (SC), intraperitoneally (IP) and/or intravenously (IV) or locally into CNS 
(neocortex, hippocampus, amygdala, SN, area tempests). PTZ can be administrated once, 
repetitively or continuously (as intravenous infusion in mice or rats). Most common 
administration is subcutaneous, minimal clonic seizures induced by subcutaneous injection of 
PTZ are a part of obligatory preclinical testing of drugs.  
The calculation of the time needed to produce convulsions (seizure latency) and the 
amount of PTZ is recalculated to 50% convulsive dose expressed in mg/kg. Different 
endpoints can be used in the PTZ model: incidence of seizures, seizure severity and duration, 
as well as mortality. IV infusion allows precise calculation of various doses of PTZ 
(threshold, 50% convulsive dose, 95% convulsive dose). Seizure activity is usually monitored 
 19
by behavioral observation; EEG recording brings more data but it is time and money 
consuming. 
In the rats older than three weeks, PTZ in increasing doses can induce a nonspecific 
activation at the beginning and then four different epileptic phenomena. Nonspecific 
activation is represented by increased locomotor activity and orienting reaction. The first 
epileptic event is characterized by behavioral arrest (freezing) with episodes of spike-and-
wave activity (sometimes in a spindle-like form) in the EEG. Duration of these episodes is 
usually between five and ten seconds. The second phenomenon is formed by isolated 
myoclonic twitches of whole body mostly with isolated sharp waves in EEG recording. 
Clonic seizures restricted to head and forelimb muscles (minimal seizures) represent the third 
event. They last some tens of seconds and are accompanied by spike-and-wave rhythm in the 
EEG. Finally, generalized seizures (major seizures) with tonic and clonic phases can be 
observed with whole spectrum of EEG changes (irregular high-amplitude spikes, slow waves 
forming spike-and-waves complexes and dysrhythmic activity). In addition, increasing doses 
shorten the latency to onset of seizures, augment the severity of convulsions and induce also 
an incidence of lethal outcome. Moreover, the observed initial stages can fail to appear if high 
doses are used (de Casrilevitz M. et al. 1971; Mares P. and Schickerova R. 1980a; Mares P. 
et al. 1980b; Mares P. and Velisek L. 1983; Vernadakis A. and Woodbury D. M. 1969).  
In rodents, the convulsant activity changes with age (de Casrilevitz M. et al. 1971; 
Mares P. and Schickerova R 1980a; Mares P. et al. 1980b; Mares P. and Velisek L. 1983; 
Vernadakis A. and Woodbury D. M.. 1969). Animals in the first and second week of life are 
unable to generate spike-and-wave episodes with behavioral freezing as well as minimal 
clonic seizures. In contrast, single myoclonic jerks and generalized (major) seizures are not 
age-dependent and can be elicited at all developmental stages (de Casrilevitz M. et al. 1971; 
Mares P. and Schickerova R. 1980a; Mares P. et al. 1980b; Mares P. and Velisek L. 1983; 
Vernadakis A. and Woodbury D. M. 1969). Transition between the immature and mature set 
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of PTZ-induced phenomena is not abrupt. Rats in the third postnatal week can exhibit atypical 
episode of myoclonic seizures called “transitional group  (de Casrilevitz M. et al. 1971), 
imperfect form of spike-and-wave rhythm may be recorded in a part of 15-day-old rats 
(Schickerova R. et al. 1984). 
There is not only qualitative but also quantitative development of PTZ-induced 
epileptic phenomena. CD50 values of PTZ for motor seizures differ in rats from postnatal day 
7 to adulthood: the lowest CD50 for generalized seizures was found in 18-day-old rats with 
higher values for both younger and older animals. There are comparable doses for adults and 
pups (7- and 12-day old), even the higher doses (CD50 = 66.6 mg/kg in 7-day-old, 58.9 
mg/kg in 12-day-old and 57.6 mg/kg in 90-day-old rats after sc administration) (Velisek L. et 
al. 1992). Similar finding was published by Vernadakis; she found the 16-day-old rats to be 
most sensitive to convulsant action of PTZ. Eighteen-day-old rats were not studied in her 
experiments (Vernadakis A. and Woodbury D. M. 1969). In contrast, CD50 for minimal 
seizures decreases from postnatal day 18 up to adulthood (Velisek L. et al. 1992). 
It is always necessary to take into account strain (and probably also breeding) 
differences if outcome of individual studies is compared (de Casrilevitz M. et al. 1971; Mares 
P. et al. 1980a; Mares P. et al. 1980b; Mares P. et al. 1983; Vernadakis A. and Woodbury D. 
M. 1969). 
There are some important features of different application routes. Timed intravenous 
PTZ infusion into tail vein substantially decreased number of animals, which are necessary to 
have statistically valid data. If more than one endpoint is used in this test, this way of 
administration yields very detailed data (Loscher W. 2009). On the other hand, this type of 
application is much more time consuming and therefore it is not used by pharmaceutical 
companies. An additional problem is in intravenous application in very young rodents 
(Loscher W. 2009). 
 
 21
2.2. NMDA-induced seizures as a model of age-dependent seizures 
Seizures induced by methylated aspartate do not represent a common model. They are 
used only in a few laboratories. 
NMDA (methylated aspartate) or racemic mixture N-methyl-DL-aspartate (NMDLA) 
is well dissolved in normal saline and to elicit motor seizures it can be administered 
intracerebrally (Lees G. J. 1995), intracerebroventricularlly (ICV) (Swinyard E. A. et al. 1991) 
or more often systematically (IP) by a single bolus injection (Singh L. et al. 1991) or by 
intravenous infusion (Singh L. et al. 1991).  
Description of seizures elicited by systemically administered NMDLA in adult mice 
was published by Singh (1991). Clonic-tonic generalized seizures described by Singh could 
be elicited also after focal microinjection into brain tissue such as unilateral amygdala 
(Hirayasu Y. and Wada J. A. 1992), massa intermedia (in the middle thalamus) (Ishimoto T. et 
al. 2000) or hippocampus (Lees G. J. 1995).   
Systemic administration of NMDA induced in adult rodents hyperlocomotor activity, 
(running typically in “eight-shaped“ trajectory) and extreme agitation as the first sign. 
Intensity of this locomotor activity increases with the dose of NMDA. The hyperactivity is 
later replaced by ataxia and then by automatisms (tail flicking and/or biting of the tail or 
paws). These phenomena probably represent the first specific stage of NMDA-induced 
epileptic activities. Next step is formed by generalized clonic-tonic seizures. If the animals 
progress up to this stage, mortality is practically 100%.  
All these phenomena could be observed also in immature rats but the sensitivity is 
extremely high in 7-day-old rats and decreases with age (Mares P. and Velisek L. 1992). What 
is different is the intensity of individual events, especially of hyperlocomotion. It is highly 
expressed in 25-day-old rats, not so markedly in younger animals, probably due to the not yet 
fully mature motor abilities. A special pattern of seizures appears during the first three 
postnatal weeks. This type of seizures – flexion - is specific for convulsant drugs acting on 
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NMDA receptors, it cannot be elicited by agonists of AMPA or kainate receptors. The 
hyperflexion of head, body and tail with a loss of righting ability and with or without sound 
effects called emprosthotonus (“ball” position). Eighteen-day-old rats exhibit flexion seizure 
(emprosthotonus) after lower doses of NMDA; if high doses are used they can be masked by 
generalized seizures which appear with a short latency  (Mares P. and Velisek L. 1992). 
EEG correlate in cortical and hippocampal recording is not specific. Generally, 
amplitude suppression occurs almost immediately after NMDA administration in young as 
well as adult animals. It can be combined with “serrated” waves (consisting of fast low-
voltage activity superimposed on huge slow waves) (our data) accompanying the behavioral 
arrest. Almost isoelectric lines mixed with slow hippocampal waves are recorded during the 
flexion seizures (our data).  
 
2.3. Flurothyl-induced seizures in immature rats 
Flurothyl [bis (2,2,2-trifluoroethyl) ether] when inhaled is a potent CNS stimulant and 
a rapidly acting volatile convulsant (Krantz J. C., Jr. et al. 1957; Truitt E. B., Jr. and 
Ebersberger E. M. 1960). The mechanism of the flurothylinduced convulsant effect is 
unknown. Flurothyl may affect synaptic transmission either presynaptically, postsynaptically, 
or both (Richter J. et al. 1977; Schuck S. L. and Shulman A. 1971).  
The behavioral pattern of flurothyl induced seizures is age dependent (Sperber E. F. 
and Moshe S. L. 1988). In young adult rats (postnatal days [PN] 60), flurothyl initially 
induces clonic seizures consisting of head and forelimb clonus with preservation of the 
righting reflex. Several episodes of clonic seizures can occur. With increasing amounts of 
flurothyl, tonic or tonic-clonic seizures appear characterized by wild running and loss of the 
righting reflex. Thirty-day-old rats (PN 30) display “adult-like’’ behavioral seizure patterns 
(Veliskova J. 1999). In rat pups (PN 9 and PN 15), a clonic seizure is followed almost 
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immediately by a tonic-clonic seizure. The latency to seizure onset is also age dependent 
(Sperber E. F.and Moshe S. L. 1988; Velisek L. et al. 1995a). 
 
3. Anticonvulsant drugs with mechanism of action connected with 
GABAergic inhibition 
3.1. Ganaxolone 
Neurosteroids are steroid hormones that can be formed de novo in the central nervous 
system (CNS) (Baulieu E. E.1981). Neurosteroids can also be produced in brain tissues from 
the conversion of peripheral steroid hormones such as progesterone, deoxycorticosterone, and 
testosterone, which can cross the blood-brain barrier (Majewska M. D. 1992). Endogenous 
neurosteroids as well as synthetic neuroactive steroids alter neuronal excitability rapidly 
(within seconds to minutes) acting on the neuronal membrane (Gee K. W. et al. 1995; Paul S. 
M. and Purdy R. H. 1992). The endogenous metabolites of progesterone and their synthetic 
analogue alphaxalone are the best described neurosteroids (Gee K. W. et al. 1995; Phillipps G. 
H. 1975). There is a class of neuroactive steroids called "epalons" that are devoid of hormonal 
effects with high specific activity for the GABAA receptor complex (Baulieu E. E.1981; 
Belelli D. et al. 1989; Gee K. W. et al. 1995). Epalons interact as positive allosteric 
modulators at a unique receptor site of the GABAA receptor C1- channel complex in the CNS 
(Gee K. W. 1988; Gee K. W. et al. 1995; Harrison N. L. and Simmonds M. A. 1984; 
Majewska M. D. et al. 1986; Majewska M. D. 1992; Paul S. M. and Purdy R. H. 1992). As 
positive modulators of GABAA receptor complex, epalons have anticonvulsant effects 
(Majewska M. D. 1992). Ganaxolone (hydroxy-3P-methyl-pregnan-20- one; GNX) is a newly 
developed 3P-methylated synthetic epalon derived from the endogenous neuroactive steroid 
3-hydroxy-5-pregnan-20-one (3ά,5ά-P) (Carter R. B. et al. 1997; Monaghan E. P. et al. 
1997). GNX was developped to avoid rapid catabolism characteristic for natural metabolites 
of progesterone. 
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In vitro studies show that GNX has a positive allosteric modulatory effect at the 
GABA, receptor-Cl- channel complex (Carter R. B. et al. 1997). Data from in vivo studies 
demonstrate that GNX is a potent anticonvulsant against clonic pentylenetetrazol (PTZ)-, 
bicuculline-, t-butylbicyclophosphorothionate-, cocaine-, and aminophylline-induced seizures 
after systemic administration in adult rats or mice (Carter R. B. et al. 1997; Gasior M. et al. 
1997). Systemic GNX administration exhibits a protective effect against stage 5 kindled 
convulsions produced by corneal kindling in adult rats (Carter R. B. et al. 1997). The 
effective doses of GNX in this study are below those that induce ataxia in rotorod test. Tonic 
convulsions induced by maximal electroshock are also effectively suppressed by GNX, but at 
doses that cause ataxia. This anticonvulsant effect is more pronounced in adult mice than in 
rats (Carter R. B. et al. 1997). GNX has no influence on NMDA-induced seizures but 
decreases the acute lethality of NMDA in adult mice (Laurie D. J. et al. 1992). GNX 
treatment also does not influence strychnine-induced seizures in mice (Carter R. B. et al. 
1997). It should be noted that in adult mice, the same or lower doses of GNX that produce 
anticonvulsant effects have also anxiolytic effects as tested on PTZ-induced behavioral 
changes (Hauser W. A. 1994). 
In the developing brain the anticonvulsant activity of GNX was demonstrated by our 
data and Mareš et al., (Mares P. and Stehlikova M.  2009b) in rats. Tonic-clonic seizures are 
more sensitive to GNX treatment than clonic seizures in PTZ-induced convulsions (Mares P. 
and Stehlikova M. 2009b). Interestingly, PTZ-induced minimal clonic seizures are not 
influenced by GNX (Mares P. and Stehlikova M. 2009b). However, minimal clonic seizures 
can be elicited only after the third postnatal week of rats following PTZ administration 
(Mares P. and Schickerova R.  1980a; Mares P. and Velisek L.. 1983). GNX was active in the 
model of epileptic afterdischarges (ADs) induced by electrical stimulation of sensorimotor 
cortical region in developing rats (Mares P. 2005; Mares P. and Stehlikova M. 2009b). 
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The best anticonvulsant effects of GNX were prominent in PN 12 rats (Mares P. et al. 
2009a) in PTZ model, as well as in cortical epileptic ADs. 
The effects are dose dependent (our data) and lasted for at least 60 min. Similar data 
were obtained with anticonvulsant action of THDOS conjugate (triethylammonium 3-
hydroxy-20-oxo-5 pregnan-21yl hydrogrnsuccinate) and HOHP (3alpha-hydroxy-21xi,22-
oxido-21-homo-5alpha-pregnan-20-on ) as demonstrated by Mareš at all in PN12 rats (Mares 
P. 2005; Mares P. et al. 2006). The effects of GNX in the flurothyl model are most prominent 
when the drug is administered 10 min before testing. This finding is in agreement with the 
time-course data of a previous study in adult mice and rats that demonstrated the best effects 
of GNX shortly (10 min) after GNX administration (Carter R. B. et al. 1997).  
Preclinical and clinical studies described side effects of GNX (Laxer K. et al. 2000; 
Mares P. and Stehlikova M. 2009b; Pieribone V. A. et al. 2007). GNX treatment produced 
ataxia when tested on the rotorod tested [Carter RB, 1997] or motor toxicity at high doses 
(TD5,, = 24.8 mg/kg in mice) as measured by inverted-screen toxicity (Gasior M. et al. 
1997)]. In cortical ADs model, GNX did not compromise motor phenomena in young animals 
(Mares P. and Stehlikova M. 2009b).  However, the most effective dose of GNX (10mg/kg) 
affected motor behavior. The side effects are collectively described as “moderate” because the 
motor activity of these animals was not fully suppressed and rats used all four limbs to pull 
themselves forward. The sedation and somnolence were the most common adverse event 
reported by patient in clinical trials (Laxer K. et al. 2000; Pieribone V. A. et al. 2007).  
 
3.2. Pyridoxine 
Vitamin B6, as a cofactor, catalyzes metabolism of various amino acids in human 
body. In the brain, its main biologically active form, pyridoxal-5'-phosphate (PLP), is 
involved in transformations of the enzymes, which play crucial roles in metabolic pathways of 
amino acids such as glutamate and GABA (Chung S. H. and Cox R. A.. 1983). Pyridoxine is 
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used as a therapeutic agent mostly is clinical neurology. Epilepsy, behavioral problems and 
other neuropsychological conditions required chronic, long-term administration of pyridoxine 
for a whole lifetime with the risk of side effects (Bernstein A. L. 1990).  
In adult patients, high vitamin B6 intake may have toxic effects in the peripheral 
nervous system (PNS) - sensory (Schaumburg H. et al. 1983; Windebank A. J. et al. 1985) as 
well as mild motor neuropathy (Morra M. et al. 1993). It is sometimes described as 
‘megavitamine’ syndrome (Dordain G. and Deffond D. 1994). Similar effects may occur after 
a chronic abuse of relatively low doses of B6 (Morra M. et al. 1993), and even modest doses 
of B6 cannot be regarded as innocent in the PNS (Bender D. A. 1989) while opposite is true 
for the central nervous system which could be protected by vitamine B6 (Snodgrass S. R. 
1992).  
In pediatric neurology, high-dose of vitamine B6 is used in treatment of rare 
intractable seizures - pyridoxine-dependent epilepsy, which is probably due to abnormal 
binding of pyridoxal phosphate to glutamic acid decarboxylase leading to a decrease of 
gamma-aminobutyric acid. Mutations in the gene encoding this enzyme may also induce 
convulsions (Bass N. E. et al. 1996; Gospe S. M., Jr. 2006; Leonard J. V. 2007; Pearl P. L. 
and Gibson K. M.  2004; Pearl P. L. et al. 2007; Pietz J. et al. 1993). Moreover, pyridoxine is 
potential antiepileptic drug, recommended in those cases where the conventional therapy 
(ACTH, oral corticosteroids or vigabatrin) of infatile spasms failed (Tsao C. Y. 2009).  
Recently another clinical disorder of GABA metabolism, the pyridoxal 5'-phosphate 
dependent seizures, has been described in infants (Gospe S. M., Jr. 2006; Leonard J. V. 2007; 
Pearl P. L. 2009). Developing CNS appears to be more sensitive to the toxic effects of B6. In 
fatal overdose with Bendectine (composed of 1:1 mixture of doxylamine succinate and 
pyridoxine HCl (Tyl R. W. et al. 1988) in an infant, tonic-clonic seizures developed as a result 
of either doxylamine or pyridoxine toxicity (Bayley M. et al. 1975). Moreover, there is a 
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report of a paradoxical rise of seizure frequency with EEG correlations developed following 
B6 administration in newborn with intractable epileptic seizures (Hammen A. et al. 1998). 
In adult patients, pyridoxine is infused in large doses as a specific antidote for 
isoniazid-induced seizures (Maw G. and Aitken P. 2003; Tai W. P. et al. 2008; Tajender V. 
and Saluja J. 2006).  
In adult rats, B6 has specific proconvulsant activity. Intravenous or 
intracerebroventricular administration of B6 induces tonic-clonic seizures with frequent lethal 
outcome (Schaeffer M. C. 1993). Therefore, the results indicate that high doses of B6 may 
have proconvulsant effects, especially in the immature brain (Ebadi M. et al. 1982; Ebadi M. 
et al. 1985).  
Multiple mechanisms of action of B6 in the brain could represent an alternative 
explanation. While low doses of B6 have anticonvulsant potency possibly due to the indirect 
support of GABA synthesis (Ebadi M. et al. 1982; Ebadi M. et al. 1985), high doses of B6 
have indeed proconvulsant effects due to unknown mechanisms (Ebadi M. et al. 1982; Ebadi 
M. et al. 1985). Studies suggest a direct interaction of high doses of B6 with the GABAA 
receptor (Ishioka N. et al. 1995) or decreasing GABA content (Waymire K. G. et al. 1995). 
Although the i.c.v. administration of B6 metabolite pyridoxal phosphate induces almost 
instant seizures (depending on the dose), it is not clear from which structure these seizures 
arise and what is the cellular mechanism of the pyridoxal seizure induction (Kouyoumdjian J. 
C. and Ebadi M. 1981;  Ebadi M. et al. 1982; Ebadi M. et al. 1985). The principal metabolite 
of B6—pyridoxal phosphate—acts as a coenzyme in many metabolic reactions (Ebadi M. et 
al. 1982; Ebadi M. et al. 1985; Kouyoumdjian J. C. and Ebadi M. 1981). Therefore, one 
could speculate about other modes of B6 action (possibly involving additional metabolic 
reactions utilizing even higher than proconvulsant doses of B6) that could supersede or mask 
proconvulsant effects of B6. 
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4. Anticonvulsant drugs with mechanism of action connected with 
glutamatergic excitation 
4.1. MK-801 (dizocilpine) 
The anticonvulsant, central sympathomimetic and anxiolytic properties of compound 
MK-801 [(+)- 10,11-dihydro-5-methyl-5H-dibenzo (a,d) cycloheptene-5,10 imine] were 
described (Clineschmidt B. V. et al. 1982a; Clineschmidt B. V. et al. 1982b; Clineschmidt B. 
V. et al. 1982c). MK801 is a selective, non-competitive antagonist of excitatory amino acid 
transmitters at the NMDA receptor site (Woodruff G. N. et al. 1987). High effectiveness of 
MK-801 against epileptic seizures induced in vivo (Clineschmidt B. V. et al. 1982a) also led 
to the use of this anticonvulsant in a clinical study  (Troupin A. S. et al.1986).  In clinical trials 
MK-801 in high doses is effective against epileptic seizures, but it induced psychomimetic 
side effects. In lower doses, there is limited efficacy in treatment of epilepsy (Fisher R. and 
Blum D. 1995; Porter R. J. 1989). However, trials using MK-801 were not completely 
stopped; NMDA receptor system plays an important role in different human pathological 
states such as ischemic cerebrovascular disease (Caccamo D. et al. 2004; Giacoia G. P. 1993; 
Ginsberg M. D. 1993; Scatton B. 1994), learning and memory processes (Ciamei A. et al. 
2001; Rogawski M. A. and Wenk G. L. 2003; Tzschentke T. M. and Schmidt W.J. 2000) or 
parkinsonism (Johnston T. H. et al. 2005; Levin E. D. and Rezvani A. H. 2006; Ossowska K. 
et al. 1996; Sharp F. R. and Hendren R. L. 2007). 
Abnormal behavioral changes were observed following MK-801 IP administration. 
Hyperlocomotion  induced by MK-801 was described in rats (Frantz K. and Van Hartesveldt 
C. 1999; Koek W. et al. 1989) , guinea pigs (Jerram A. H. et al. 1996), mice (Tricklebank M. 
D. et al. 1989), pigeons (Koek W. et al. 1988; Koek W. et al. 1989) or rhesus monkeys (Koek 
W. et al. 1988). However, this motor syndrome can be facilitated by local microinjection of 
MK-801 into the posterior parts of nucleus accumbens (ACC) not into caudate-putamen (CP) 
(al-Khatib I. et al. 1995). MK-801 is the most potent noncompetitive antagonist (compared to: 
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PCP, thienylcyclohexylpiperidine (TCP), (+)-N-allylnormetazocine [+)-NANM and 
ketamine) inducing a characteristic motor syndrome in mice (Tricklebank M. D. et al. 1989), 
rats, pigeons or  rhesus monkeys (Koek W. et al. 1988).  
This behavioral, motor syndrome (MK-801-induced motor syndrome) was 
intentionally studied (Frantz K. and  Van Hartesveldt C. 1999; Hiramatsu M. et al. 1989; 
Scorza M. C. et al. 2008; Valentine J. L. et al. 1996) or mentioned as motor changes in 
different studies of anticonvulsant action (Katsumori H. et al. 1998; Stafstrom C. E. et al. 
1993). These behavioral “side” effects may be used in studies of animal models of 
schizophrenia (Ossowska K. et al. 2000) or parkinsonism (Johnston T. H. et al. 2005; Levin E. 
D. and Rezvani A. H. 2006; Ossowska K. et al. 1994; Ossowska K. et al. 1996; Sharp F. R. 
and Hendren R. L.  2007). 
In addition, MK-801 can elicit ataxia, but it is not effective as anestethic drug 
(measured by loss righting reflex) in rats. MK-801 or PCP elicit ataxia and MK-801 is 
probably toxic to Purkinje cells in cerebellum (Nakki R. et al. 1996).  
Some data indicate that behavioral changes common for all NMDA antagonists must 
not be due only to NMDA-receptor blockade. Catecholaminergic systems and serotonergic 
neurotransmission may be significantly involved in the mechanisms by which MK-801 alters 
behavior in rats (Loscher W. and Honack D. 1992).   
 
Effects of MK-801 on seizures 
There are many studies documenting the effect of MK-801 on reactive seizure in 
mature CNS. 
MK-801 prolonged latencies of PTZ-induced generalized tonic-clonic seizures in a 
dose-dependent manner. In contrast, the minimal clonic seizures remain unaffected. These 
different effects support the existence of two different generators for minimal clonic and 
generalized tonic-clonic seizures (Browning R. A. 1985; Browning R. A. and Nelson D. K.  
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1986; Gale K. 1988). According to these studies the generator of minimal seizures is 
considered to involve the structures of the forebrain ("forebrain seizures") whereas the brain 
stem structures are responsible for major (tonic-clonic) seizures. Moreover, it appears that 
NMDA receptor mediated transmission plays a dominant role in the genesis of generalized 
tonic-clonic seizures, whereas the NMDA receptor activity during clonic seizures appears to 
be less important. Pretreatment with MK-801 resulted in a dose-dependent anticonvulsant 
action in strychnine-induced generalized seizures. This action is specific - MK-801 
suppressed the tonic, but not the clonic phase of seizures in adult rats (Kubova H. and Mares 
P. 1994).  
MK-801 produced an effective and dose-dependent anticonvulsant action in the 
lithium-pilocarpine model but not in rats treated with a high dose pilocarpine alone (Ormandy 
G. C. et al. 1989). In contrast, MK-801 was found to exhibit proconvulsant action in the 
mouse pilocarpine model of complex partial seizures (Starr M. S. and Starr B. S. 1993). In the 
kainate model of limbic seizures in rats, MK-801 markedly reduced number of wet dog 
shakes as well as seizure severity elicited by kainate (Loscher W. et al. 1994). MK-801 also 
reduced cocaine- and methamphetamine-induced seizures in rats (Derlet R. W. et al. 1990). If 
MK-801 was administered intracerebroventricularly together with NMDA it antagonized 
NMDA-induced generalized seizures (Chiamulera C. et al. 1990). 
MK-801 blocked motor seizures induced by electrical stimulation of hippocampal or 
amygdala kindled foci, but was more effective in reducing seizure severity and AD duration 
resulting from stimulation of the hippocampal focus (Gilbert M. E. 1988). MK-801 prevented 
an increase of the duration of maximal dentate activation; in addition, higher doses of MK-
801 shortened the duration of maximal dentate activation (Stringer J. L. and Lothman E. W.  
1990). MK-801 was found to be potent against the spread of seizures but less effective against 
partial seizures (Williamson J. M. and Lothamn E. W. 1989). The effect of single 
administration of MK-801 on the induction of audiogenic seizure susceptibility by noise in 
 31
immature rats was examined. Treatments with this non-competitive N-methyl-D-aspartate 
(NMDA) receptor antagonist resulted in increases in noise exposure-dependent susceptibility 
(Pierson M. and Swann J. 1991).  
MK-801 paradoxically enhanced electrographic seizures that preceded SE suppression 
in a model of limbic SE induced by 90 min of 'continuous' electrical stimulation of the 
hippocampus in rats (Bertram E. H. and Lothman E. W. 1990).  
The data from the preclinical studies, where the action of MK-801 is tested in different 
models of epileptic seizures and the behavioral “side effects” models during ontogenesis in 
animals, suggested that MK-801 might affect not only NMDA receptor system.  
 
4.2. 2-amino-7-phosphonoheptanoic acid (AP7) 
One of ω-phosphonic amino acids, 2-amino-7-phosphonoheptanoic acid (AP7) was 
shown to be a potent competitive antagonist of N-methyl-D-aspartate (NMDA) receptors 
(Evans R. H. et al. 1982).  This antgonism is a background for its anticonvulsant action 
(Chapman A. G. et al. 1991).  
Anticonvulsant effect of AP7 has been studied in several types of experimental 
seizures in adult animals. Seizures produced by N-methyl-D-aspartic acid (NMDA) (Meldrum 
B. S. et al. 1983) were antagonized by pretreatment of AP7 and the same was demonstrated 
for clonic seizures induced by IP, SC or IV administration of N-methyl-DL-aspartic acid 
(NMDLA) (Czuczwar S. J. and Meldrum B. 1982; Czuczwar S. J. et al. 1985).  
Similar anticonvulsant effect was demonstrated against seizures elicited by kainic acid 
(KA), 3-mercaptopropionic acid (3MPA), thiosemicarbazide (TSC), quinolinic acid, 
bicuculline, picrotoxin (Czuczwar S. J. and  Meldrum B. 1982; Nevins M. E. and Arnolde S. 
M. 1989) and methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) 
(Czuczwar S. J. and Meldrum B. 1982), or PTZ (Croucher M. J. et al. 1982; Nevins M. E. and 
Arnolde S. M. 1989). Pretreatment of DBA/2 mice (a strain of mice genetically susceptible to 
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sound-induced seizures) with AP7 blocked myoclonus or convulsions induced by trans-2,3-
piperidine dicarboxylic acid (Croucher M. J. et al. 1984). Also, intracerebroventricular 
administration of AP7 acts against NMDA-induced clonic seizures (Meldrum B. S. et al. 
1983) and 4-aminopyridine (4-AP)-induced generalized tonic-clonic seizures (Fragoso-Veloz 
J. and Tapia R. 1992). Moreover, AP7 protects against tonic extension seizures in 
submaximal and maximal electroconvulsive shock (ECS) models (Nevins M. E. and Arnolde 
S. M. 1989) or blocks the full motor seizures (stage 5) in electrical stimulation of the ventral 
hippocampus (Peterson D. W. et al. 1984) or prevented the development of seizure activity in 
amygdala kindling (Croucher M. J. et al. 1995). 
However, AP7 is less potent than noncompetitive NMDA antagonist (MK-801, PCP) 
(Fragoso-Veloz J. and Tapia R. 1992; Nevins M. E. and Arnolde S. M. 1989).  
Protective effect of focal microinjections of AP7 into different CNS structures was 
demonstrated in model of limbic seizures. Bilateral application of AP7 into the 
entopeduncular nucleus (EP) (Patel S. et al. 1986), into the prepiriform cortex (PC) (Millan 
M. H. et al. 1986) or into the substantia nigra (SNR) pars reticulata (Turski L. et al. 1986) 
prevented pilocarine-induced seizures (Millan M. H. et al. 1986; Patel S. et al. 1986; Turski L. 
et al. 1986); bilateral application into substantia nigra (SNR) pars reticulata suppressed PTZ-
induced tonic seizures (Xie X. H. et al. 1991) and unilateral injection into deep prepiriform 
cortex (DPC) prevented seizures induced by the intravenous administration of bicuculline in 
the rat (Piredda S. and Gale K. 1986).  
Interestingly, the focal bilateral infusion of AP7 into (SNR) pars reticulata increased 
duration of electrographic KA-induced seizure discharges (Tanaka K. et al. 1994) or 
prolonged seizure duration in KA-induced status (Tanaka K. et al. 1996).  These authors 
speculate that differences in seizure models may account for these contradictory findings. 
Recently, difference between two parts of SNR anterior and posterior was demonstrated to 
exhibit site-specific effects on seizures (Fan X. D. et al. 1997; Moshe S. L. et al. 1994; 
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Thompson K. et al. 2000; Veliskova J. and Moshe S. L. 2001). Bilateral microinfusions of 
GABAA agonists in the SNRanterior have anticonvulsant effects, while they have 
proconvulsant effects in the SNRposterior (Thompson K. et al. 2000; Veliskova J. et al. 1996). 
The same site-specificity was demonstrated for AP7 in the adult male rats. Anticonvulsant 
effects of AP7 infusions were demonstrated in the SNRanterior in agreement with data for 
other seizure models (De Sarro G. et al. 1984; Maggio R. and Gale K. 1989; Turski L. et al. 
1986; Wurpel J. N. et al. 1992). The proconvulsant effect of AP7 infusions in the 
SNRposterior is consistent with the findings of Tanaka et al. (Tanaka K. et al. 1994).  
Blockade of NMDA receptors in both SNR subregions produced effects similar to 
augmentation of GABAergic neurotransmission (using intranigral infusions of GABAA 
receptor agonists) (Moshe S. L. et al. 1994; Thompson K. et al. 2000; Veliskova J. et al. 1996). 
Infusions of acidic solution in the SNRposterior have proconvulsant effects (Velisek L. et al. 
1998). A possible mechanism may be the suppressive effect of acidosis on NMDA receptors 
leading to a decrease in neuronal excitability (Tang C. M. et al. 1990; Traynelis S. F. and 
Cull-Candy S. G. 1990), similar to the effect of AP7 infusions. The protons may also produce 
agonist-like effects on GABAA receptors (Kaila K. 1994); the proconvulsant effects of local 
pH changes in the SNRposterior are similar also to the effects of GABAA agonists in this 
region (Moshe S. L. et al. 1994; Velisek L. et al. 1998). These data show that the effects of the 
specific NMDA receptor antagonist AP7 are region specific. The substantia nigra pars 
reticulata (SNR) plays an important age- and sex-specific role in control of clonic seizures. Its 
involvement in control of tonic-clonic seizures is contradictory (Velisek L. et al. 2006).   
NMDA receptor sensitivity changes during ontogenesis, higher efficacy was 
demonstrated in young animals (Baudry M. et al. 1983; Tsumoto T. et al. 1987; Velisek L. et 
al. 1990; Wurpel J. N. et al. 1992). Developmental studies of anticonvulsant action of AP7 are 
restricted to PTZ-induced generalized tonic-clonic seizures (Velisek L. et al. 1990), 
homocystein (Folbergrova J. 1997) and homocysteic acid (Folbergrova J. et al. 2000). The 
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marked anticonvulsant effect of this competitive NMDA antagonist - AP7 during 
development has been demonstrated however the strong unwanted side effects make some 
limitations (Mares P. et al. 2004).  
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AIMS OF STUDY 
 
1. To study anticonvulsant action of drugs influencing inhibitory GABAergic system against 
seizures elicited by convulsants with different mechanisms of action during development. 
 
2. To verify age-specific model of flexion seizures in immature rats by means of 
pharmacological intervention with drugs used in pediatric epileptology (with a focus on 
GABAergic system). 
 
3. To study anticonvulsant action of drugs influencing excitatory glutamatergic system at 
different levels of brain maturation. 
 
4. To analyze possible site of anticonvulsant action of antagonists of glutamate receptors of 
the NMDA type. 
 
5. The general aim was to test the hypothesis that correction of the balance between inhibitory 
and excitatory systems is a possible way to efficient treatment of epileptic seizures at different 







The main question posed at the beginning of this dissertation – if the disbalance 
between excitatory and inhibitory systems in the brain which form a background of nearly all 
types of epileptic seizures – may be answered positively. We were able to suppress epileptic 
seizures elicited by an insult targeted on one of these systems by a therapeutic intervention 
focused on the opposite system at all developmental stages studied. This question is important 
due to increasing amount of data demonstrating that the main inhibitory neurotransmitter in 
the mature brain, GABA, serves as an excitatory factor at early stages of development in 
relation to intracellular activity of chloride anions (Ben-Ari Y., 2002; Dzhala V. I. et al. 2005). 
Our data clearly show that this excitatory action is restricted to the very first postnatal days (in 
hippocampus, data for other brain structures are sparse) and that rats in the second week of 
life exhibit normal, i.e. inhibitory action of GABA. 
Our results demonstrated that it is possible to induce experimentally a model of some 
features of age-specific seizures and affect them pharmacologically similarly to clinical 
experience with epileptic syndromes in pediatric epileptology. NMDA-elicited flexion 
seizures model a type of seizures typical for Lennox-Gastaut syndrome in infancy and were 
recently used as an important part of a model of this severe age-dependent epileptic syndrome 
(Velisek L. et al. 2007). An elaboration of this model is based on description of these specific 
seizures by Mareš and Velíšek (1992) and pharmacological verification presented in these 
theses. 
In addition to special discussions in all papers included in these theses two points 
deserve special attention: 1) proconvulsant and convulsant action of pyridoxine and 2) site-
specific anti- or proconvulsant action of NMDA receptor antagonist (AP7) in substantia nigra. 
Ad 1) Pyridoxine is a coenzyme of many enzymes mostly those involved in 
metabolism of amino acids. Among these enzymes is glutamate decarboxylase, an enzyme 
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which produces GABA from glutamic acid, as well as GABA-aminotransferase, an enzyme 
playing a key role in catabolism of GABA (Amadasi A. et al. 2007). Low doses exhibited 
expected anticonvulsant action probably by potentiation of glutamate decarboxylase activity 
but high doses (250 mg/kg) induced seizures. These seizures are nonconvulsive, they are 
hardly detectable without EEG recording. Mechanism of generation of these seizures is not 
known but increased activity of GABA-aminotransferase should be taken into account and 
changes of activity of other enzymes cannot be excluded.  In spite of the fact that the 250-
mg/kg dose is extremely high, this finding may be of clinical significance.  
Ad 2) Different role of GABA receptors in anterior and posterior parts of substantia 
nigra in epileptic seizures was described. Effects of drugs potentiating GABAergic inhibition 
(muscimol, vigabatrin) or suppressing it (bicuculline) can be anticonvulsant or proconvulsant 
according to the site of microinjection (Moshe S. L. and Garant D. S. 1996, Veliskova J. et al. 
1996). Our data demonstrated that this region-specific effect is not bound to GABAergic 
system only and that antagonists of NMDA receptors exhibit the same site specificity as 
GABAergic drugs. An injection of AP7 into anterior part of substantia nigra resulted in an 
anticonvulsant action whereas injection into posterior part had a proconvulsant action. These 
parallels between effects of GABAergic and glutamatergic drugs demonstrated again a 
significance of balance between the two main neurotransmitter systems for generation as well 
as suppression of epileptic seizures. 
Our results clearly shown that different types of epileptic seizures can be elicited if 
excitation prevails over inhibition and that this is valid for all developmental stages studied. 
None of our studies included rat pups in the first week of postnatal life where the role of 
GABA may be excitatory rather than inhibitory. Older data from our laboratory demonstrated 
that the inhibitory function of GABA expressed as an anticonvulsant action of drugs 
potentiating GABAergic inhibition is present even in 7-day-old rats (Kubova H. and Mares P. 
1991). Local application of bicuculline, a competitive antagonist of GABA, on the cerebral 
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cortex, induces an epileptiform focus even in 5-day-old rats (Velískova J. et al. 1991). The 
balance between excitation and inhibition can be compromised as well as repaired by 
intervention in either system. This general principle is valid at all developmental stages 
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